Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ: IRON )

64.94 +1.43 (+2.25%)
Streaming Delayed Price Updated: 10:41 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Disc Medicine, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Crude Oil Moves Higher; Oxford Industries Shares Fall After Q4 Results
U.S. stocks traded lower midway through trading, with the Dow Jones falling over 300 points on Monday. The Dow traded down 0.79% to 39,492.80 while the NASDAQ fell 0.22% to 16,344.11. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Disc Medicine Stock Plunges As Light Sensitivity Treatment Data Confounded Due To Outsized Placebo Response
Disc Medicine releases AURORA Phase 2 study data on bitopertin for Erythropoietic Protoporphyria. Significant reductions in PPIX levels and improvements in phototoxic reactions observed with bitopertin... 
Via Benzinga
Disc Medicine Plummets 59% After Placebo Effect Confounds Sunlight Sensitivity Study
The company is hoping to treat a rare disease that causes patients to experience severe reactions to sunlight. 
Via Investor's Business Daily
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
NASDAQ:IRON Shareholder Notice: Investigation over Potential Wrongdoing at Disc Medicine Opco Inc
San Diego, CA -- (SBWIRE) -- 12/08/2023 -- Certain directors of Disc Medicine Opco Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
From Disc Medicine Inc
Via GlobeNewswire
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... 
Via Talk Markets
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous successful launches 
From Disc Medicine Inc
Via GlobeNewswire
Where Disc Medicine Stands With Analysts
Via Benzinga
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
From Disc Medicine Inc
Via GlobeNewswire
Blue Bird Posts Upbeat Results, Joins Oil-Dri Corporation of America, Eagle Bulk Shipping And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
From Disc Medicine Inc
Via GlobeNewswire
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
From Disc Medicine Inc
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.